The fresh energy brought by the revitalized research attention offers an opportunity to more closely integrate novel drug discovery, residue monitoring, and ...

Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key ...

The ancient Greek physician and botanist Dioscorides is considered by many to be the father of pharmacology for authoring De ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the ...

Natural products are essential sources of bioactive compounds for drug discovery. While earlier drug development relied on targeting single molecules to ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...

Pharmacokinetics: The pharmacokinetic profile of DF-003 was largely dose proportional and the data support additional clinical trials as a once-daily, orally administered drug.